All In Biotech

Drug Trial Radar · NCT06191640

Sinus Disease in Young Children With Cystic Fibrosis

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 12, 2023

Primary completion

Jun 30, 2029

Study completion Jun 30, 2029

Sponsor

Lead sponsor
University of California, Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Kansas Medical Center; Children's Hospital Medical Center, Cincinnati; University of Iowa; University of Virginia; University of Vermont; University of North Carolina, Chapel Hill; Children's Hospital Colorado
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Outcomes will include sinus magnetic resonance imaging (MRI) scans, olfactory tests, and quality of life surveys obtained over a two-year period.

Conditions

  • Cystic Fibrosis in Children
  • Cystic Fibrosis
  • Chronic Rhinosinusitis (Diagnosis)
  • Olfactory Disorder
  • Olfactory Impairment

Interventions

  • Ivacaftor or elexacaftor/tezacaftor/ivacaftorDrug

    HEMT's are prescribed at the discretion of the treating physician and is not dictated by the principal investigator of this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in MRI sinus opacificationTime frame: Baseline, 1-year, and 2-year follow-up
  2. Change in olfactory bulb volumeTime frame: Baseline, 1-year, and 2-year follow-up

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • University of Vermont

    Colchester, Vermont · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.